Krystal Biotech (NASDAQ:KRYS) Posts Earnings Results, Beats Estimates By $0.38 EPS

Krystal Biotech (NASDAQ:KRYS) posted its quarterly earnings results on Monday. The company reported $1.83 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.45 by $0.38, FiscalAI reports. The business had revenue of $116.36 million for the quarter, compared to the consensus estimate of $112.11 million. Krystal Biotech had a return on equity of 18.69% and a net margin of 52.64%.

Krystal Biotech Stock Performance

Krystal Biotech stock opened at $266.04 on Monday. The stock has a 50-day moving average of $261.72 and a two-hundred day moving average of $246.50. Krystal Biotech has a one year low of $122.80 and a one year high of $298.30. The stock has a market cap of $7.83 billion, a PE ratio of 38.84 and a beta of 0.50.

Insiders Place Their Bets

In other Krystal Biotech news, Director Daniel Janney sold 11,803 shares of the stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $275.59, for a total value of $3,252,788.77. Following the completion of the sale, the director directly owned 73,293 shares in the company, valued at approximately $20,198,817.87. This trade represents a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CAO Kathryn Romano sold 750 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $267.60, for a total value of $200,700.00. Following the completion of the sale, the chief accounting officer owned 22,366 shares of the company’s stock, valued at approximately $5,985,141.60. This trade represents a 3.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 129,164 shares of company stock valued at $34,538,578. 13.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Krystal Biotech

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Greenline Wealth Management LLC purchased a new stake in Krystal Biotech in the fourth quarter valued at about $34,000. UMB Bank n.a. raised its stake in Krystal Biotech by 34.6% in the fourth quarter. UMB Bank n.a. now owns 144 shares of the company’s stock valued at $36,000 after buying an additional 37 shares during the last quarter. Global Retirement Partners LLC raised its stake in Krystal Biotech by 788.9% in the fourth quarter. Global Retirement Partners LLC now owns 160 shares of the company’s stock valued at $39,000 after buying an additional 142 shares during the last quarter. Danske Bank A S purchased a new stake in Krystal Biotech in the third quarter valued at about $35,000. Finally, Wilmington Savings Fund Society FSB raised its stake in Krystal Biotech by 78.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 393 shares of the company’s stock valued at $69,000 after buying an additional 173 shares during the last quarter. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on KRYS. Citigroup upped their price objective on Krystal Biotech from $336.00 to $371.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Chardan Capital upped their price objective on Krystal Biotech from $220.00 to $323.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Zacks Research cut Krystal Biotech from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 5th. Weiss Ratings upgraded Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Thursday, April 9th. Finally, Guggenheim upped their price objective on Krystal Biotech from $224.00 to $284.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Nine investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $326.25.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.